



Express Mail Label No.: EL93281883US

Date of Deposit: January 17th, 2002

PATENT

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Sedivy et al.

U.S. Serial No.: 09/654,281

Filed: 09/01/2000

Entitled: Kinase Inhibitors and Methods of Use
in Screening Assays and Modulation of
Cell Proliferation and Growth

Group: 1642

Examiner: Tran, M

TECH CENTER 1600/2900

JAN 30 2002

RECEIVED

Attorney Docket No.: 3564/1010

BOX SEQUENCE

Commissioner for Patents and Trademarks

Washington, D.C. 20231

**AMENDMENT AND RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR
PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Sir:

The following is submitted in response to the Notice to Comply With Requirements For Patent Applications Containing Nucleotide And/Or Amino Acid Sequence Disclosures mailed by the PTO on December 6th, 2001.


Submitted herewith are a substitute paper copy of the "sequence listing" and a substitute computer readable form (CRF) of the "sequence listing".

Applicants, in compliance with 37 C.F.R. 1.821(f), hereby state that the information recorded in computer readable form submitted herewith is identical to the written sequence listing. Applicants, in compliance with 37 C.F.R. 1.821(g), further state that the substitute sequence listing adds no new matter.

Respectfully submitted,

Date: 1/17/02

Kathleen M. Williams
Reg. No. 34,380
PALMER AND DODGE, LLP
111 Huntington Avenue
Boston, MA 02199-7613 (617) 239-0451



Notice to Comply

Application No.	Applicant(s)	
09/654,281	SEDIVY PH.D. ET AL.	
Examiner	Art Unit	
Stephen L. Rawlings, Ph.D.	1642	

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other:

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY